

Juan C Hernández-Boluda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449367/publications.pdf>

Version: 2024-02-01

158
papers

4,711
citations

109321

35
h-index

123424

61
g-index

162
all docs

162
docs citations

162
times ranked

4687
citing authors

#	ARTICLE	IF	CITATIONS
1	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
2	Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. <i>Leukemia</i> , 1999, 13, 150-154.	7.2	205
3	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010, 116, 1205-1210.	1.4	202
4	Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , 2012, 119, 1363-1369.	1.4	198
5	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007, 21, 143-150.	7.2	167
6	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , 2004, 127, 399-403.	2.5	125
7	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	3.5	118
8	Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. <i>Leukemia</i> , 2007, 21, 1218-1223.	7.2	112
9	Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3311-3318.	3.9	109
10	Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. <i>Frontiers in Oncology</i> , 2019, 9, 603.	2.8	90
11	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	6.2	80
12	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	7.2	75
13	Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2011, 152, 81-88.	2.5	72
14	Allogeneic transplantation of CD34+selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?. <i>Blood</i> , 2001, 98, 2352-2357.	1.4	71
15	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	7.2	70
16	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
17	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2006, 134, 184-186.	2.5	67
18	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014, 93, 2037-2043.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. <i>British Journal of Haematology</i> , 2016, 172, 786-793.	2.5	60
20	Reconstitution of CMV pp65 and IE-1-specific IFN- γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 1437-1443.	2.4	59
21	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , 2015, 94, 1791-1796.	1.8	57
22	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010, 95, 1317-1324.	3.5	53
23	Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN- γ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2010, 45, 543-549.	2.4	53
24	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 1014-1019.	0.8	52
25	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	3.5	52
26	JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. <i>Haematologica</i> , 2007, 92, 1717-1718.	3.5	51
27	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.	3.5	51
28	Danazol treatment of idiopathic myelofibrosis with severe anemia. <i>Haematologica</i> , 2000, 85, 595-9.	3.5	51
29	Enumeration of cytomegalovirus-specific interferon- γ CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , 2008, 93, 1434-1436.	3.5	49
30	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2015, 94, 911-918.	1.8	49
31	Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. <i>Bone Marrow Transplantation</i> , 2005, 36, 847-853.	2.4	47
32	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
33	JAK2 V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events. <i>American Journal of Hematology</i> , 2014, 89, 517-523.	4.1	40
34	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , 2017, 38, 1213-1221.	1.9	40
35	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	4.1	40
36	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. <i>Experimental Hematology</i> , 2003, 31, 204-210.	0.4	39

#	ARTICLE	IF	CITATIONS
37	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	6.2	38
38	A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228.	1.4	37
39	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
40	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
41	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021, 35, 2445-2459.	7.2	36
42	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 397-400.	2.5	34
43	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
44	An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 653-661.	2.0	33
45	Kinetics of cytomegalovirus (CMV) pp65 and IE-specific IFN γ CD8 ⁺ and CD4 ⁺ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection. <i>Journal of Medical Virology</i> , 2010, 82, 1208-1215.	5.0	31
46	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
47	Imatinib mesylate (Gleevec(R)/Glivec(R)): A new therapy for chronic myeloid leukemia and other malignancies. <i>Drugs of Today</i> , 2002, 38, 601.	2.4	31
48	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2000, 65, 104-108.	2.2	30
49	Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. <i>Blood Cancer Journal</i> , 2021, 11, 16.	6.2	29
50	Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. <i>British Journal of Haematology</i> , 2013, 161, 865-871.	2.5	27
51	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	2.2	26
52	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 717-722.	1.3	26
53	XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2010, 85, 482-486.	4.1	26
54	Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. <i>Annals of Hematology</i> , 2013, 92, 771-775.	1.8	26

#	ARTICLE	IF	CITATIONS
55	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	6.2	26
56	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	6.2	26
57	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , 2003, 88, 1117-22.	3.5	26
58	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	17.0	26
59	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2160-2172.	2.4	25
60	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
61	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	2.4	24
62	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , 2017, 98, 407-414.	2.2	23
63	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22
64	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	2.5	22
65	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22
66	Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2000, 38, 83-90.	1.3	21
67	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2019, 98, 321-330.	1.8	21
68	Impact of cytomegalovirus <scp>DNA</scp>emia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18
69	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. <i>Leukemia</i> , 2020, 34, 2648-2659.	7.2	18
70	Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 174-181.	0.8	17
71	Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 96, 285-290.	2.2	17
72	A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , 2017, 19, e12729.	1.7	17

#	ARTICLE	IF	CITATIONS
73	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
74	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
75	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020, 99, 791-798.	1.8	17
76	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
77	Unmet clinical needs in the management of CALR-mutated essential thrombocythemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , 2021, 8, e658-e665.	4.6	17
78	Target hematologic values in the management of essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2015, 94, 4-11.	2.2	16
79	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.	1.3	16
80	Prognostic factors in chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 343-353.	1.7	15
81	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , 2018, 61, 206-212.	4.0	15
82	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
83	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
84	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. <i>Cancer</i> , 2022, 128, 2441-2448.	4.1	14
85	Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , 2016, 9, 489-496.	2.2	13
86	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	1.8	13
87	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	2.4	13
88	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020, 22, e13206.	1.7	13
89	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018, 67, 805-807.	5.8	12
90	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	2.4	12

#	ARTICLE	IF	CITATIONS
91	Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2251.	2.4	12
92	Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. <i>Leukemia Research</i> , 2020, 91, 106338.	0.8	12
93	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. <i>Leukemia</i> , 2021, 35, 623-627.	7.2	12
94	European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. <i>Current Research in Translational Medicine</i> , 2021, 69, 103267.	1.8	12
95	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021, 69, 103304.	1.8	12
96	Idiopathic Myelofibrosis Associated with Primary Biliary Cirrhosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 673-674.	1.3	11
97	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
98	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
99	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , 2020, 99, 527-537.	1.8	11
100	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	2.4	11
101	Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. <i>Haematologica</i> , 1999, 84, 26-31.	3.5	11
102	Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. <i>Transplant Infectious Disease</i> , 2016, 18, 89-92.	1.7	10
103	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Journal of Clinical Medicine</i> , 2021, 10, 3146.	2.4	10
104	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 500-504.	2.5	9
105	Polymyositis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2012, 96, 386-389.	1.6	9
106	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
107	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	6.2	9
108	Impact of donor-derived CD34 ⁺ cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 261-270.	2.4	9

#	ARTICLE	IF	CITATIONS
109	Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. <i>Bone Marrow Transplantation</i> , 2011, 46, 1484-1486.	2.4	8
110	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. <i>Journal of Medical Economics</i> , 2014, 17, 435-441.	2.1	8
111	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
112	Cytoreductive treatment in patients with CALR mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. <i>British Journal of Haematology</i> , 2021, 192, 988-996.	2.5	8
113	Thiotepa busulfan fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	2.4	8
114	Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 421-423.	1.3	7
115	Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , 2001, 80, 516-520.	1.8	7
116	A polymorphism in the <i>TYMP</i> gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013, 88, 883-889.	4.1	7
117	<i>BCL2</i> gene polymorphisms and splicing variants in chronic myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1278-1284.	0.8	7
118	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 813-820.	1.8	7
119	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
120	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
121	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , 2021, 62, 2040-2043.	1.3	7
122	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	2.4	7
123	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	7.2	7
124	An <i>XRCC1</i> polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1249-1254.	1.3	6
125	A <i>BCR-ABL1</i> cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. <i>PLoS ONE</i> , 2017, 12, e0173532.	2.5	6
126	Treatment of elderly patients with AML: results of an individualized approach. <i>Haematologica</i> , 1998, 83, 34-9.	3.5	6

#	ARTICLE	IF	CITATIONS
127	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , 2016, 95, 719-732.	1.8	5
128	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
129	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 740-747.	2.0	5
130	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
131	When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1448-1451.	2.4	4
132	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4
133	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
134	Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. <i>Leukemia Research</i> , 2009, 33, 589-592.	0.8	3
135	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
136	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , 2019, 39, 4757-4766.	1.1	3
137	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
138	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
139	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 152-158.	0.2	3
140	Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis. <i>Medicina Clínica</i> , 2020, 155, 152-158.	0.6	3
141	Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2017, 5, 162-174.	1.2	3
142	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. <i>Leukemia Research</i> , 2022, 115, 106821.	0.8	3
143	An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2022, , 1-8.	2.2	3
144	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018, 105, 139-143.	2.1	2

#	ARTICLE	IF	CITATIONS
145	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
146	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2
147	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
148	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
149	How I manage myeloproliferative neoplasm: Practical approaches for 2022 and beyond. <i>British Journal of Haematology</i> , 2022, , .	2.5	2
150	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. <i>Cancers</i> , 2022, 14, 2331.	3.7	2
151	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. <i>British Journal of Haematology</i> , 2022, 198, 785-789.	2.5	2
152	Impact of molecular profiling on the management of patients with myelofibrosis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102435.	7.7	2
153	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	1.3	1
154	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1
155	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2012, 36, e50-e51.	0.8	0
156	P0623 ACUTE RENAL FAILURE IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION. TWO GRAFT VS HOST DISEASE (GVHD) PROFILAXIS PROTOCOL COMPARISON. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
157	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
158	Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2022, , .	2.5	0